BCM
BML Capital Management Portfolio holdings
AUM
$131M
This Quarter Return
+1.98%
1 Year Return
+89.45%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$116M
AUM Growth
+$116M
(+11%)
Cap. Flow
-$65.9M
Cap. Flow
% of AUM
-56.95%
Top 10 Holdings %
Top 10 Hldgs %
67.62%
Holding
35
New
10
Increased
4
Reduced
8
Closed
4
Top Buys
| 1 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
$12.6M |
| 2 |
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
$9.18M |
| 3 |
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
|
$5.73M |
| 4 |
Tourmaline Bio
TRML
|
$3.63M |
| 5 |
EMBK
Embark Technology, Inc. Common Stock
EMBK
|
$3.61M |
Top Sells
| 1 |
Enliven Therapeutics
ELVN
|
$11.9M |
| 2 |
Abercrombie & Fitch
ANF
|
$7.64M |
| 3 |
Verrica Pharmaceuticals
VRCA
|
$6.24M |
| 4 |
Disc Medicine
IRON
|
$6.18M |
| 5 |
Richardson Electronics
RELL
|
$2.03M |
Sector Composition
| 1 | Healthcare | 53.31% |
| 2 | Consumer Discretionary | 14.79% |
| 3 | Technology | 5.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Lisata Therapeutics
LSTA
$19.8M
| $791K | 0.68% |
243,839
| – | – |
|
27
NextCure
NXTC
$13.3M
| $454K | 0.39% |
+25,539
| New | +$454K |
|
|
LENZ
28
LENZ Therapeutics
LENZ
$1.12B
| $373K | 0.32% |
+21,756
| New | +$373K |
|
29
Passage Bio
PASG
$22.6M
| $323K | 0.28% |
16,873
| – | – |
|
30
Adicet Bio
ACET
$60.8M
| $173K | 0.15% |
30,000
| – | – |
|
31
Neurogene
NGNE
$284M
| $16.6K | 0.01% |
+1,187
| New | +$16.6K |
|
32
CalciMedica
CALC
$45M
| – | – |
-88,282
| Closed | -$618K |
|
|
ELEV
33
DELISTED
Elevation Oncology
ELEV
| – | – |
-39,963
| Closed | -$38K |
|
|
34
Richardson Electronics
RELL
$138M
| – | – |
-95,359
| Closed | -$2.03M |
|
|
SPRB
35
DELISTED
Spruce Biosciences, Inc. Common Stock
SPRB
| – | – |
-221,830
| Closed | -$243K |
|